Acute Myeloid Leukemia
Phase 2 study findings demonstrate the clinical efficacy of pevonedistat plus azacitidine for the treatment of higher-risk MDS and low-blast AML.
The FDA has cleared an Investigational New Drug application for VOR33, an engineered hematopoietic stem cell therapy for the treatment of certain patients with AML.
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.
What is the mechanism of action of sabatolimab therapy in patients with intermediate- to high-risk MDS and/or AML?
In a phase 3 study of older patients with AML in remission after chemo, maintenance therapy with CC-486 was tied to significantly longer survival than placebo.
Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.
Patients with AML who achieved MRD negativity had significantly higher rates of OS and 5-year DFS than those with MRD, study findings show.